AJP - Endocrinology and Metabolism, Vol 269, Issue 1 E1-E9, Copyright © 1995 by American Physiological Society

ARTICLES

Receptor-mediated clearance of G-CSF derivative nartograstim in bone marrow of rats

T. Kuwabara, T. Uchimura, H. Kobayashi, S. Kobayashi and Y. Sugiyama
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.

To clarify the role of the granulocyte colony-stimulating factor (G-CSF) receptor in the nonlinear elimination of a recombinant human G-CSF derivative, nartograstim (NTG), the accompanying changes in the in vivo NTG total body clearance at steady state (CLss) or the early-phase tissue uptake clearance (CLuptake) in rats were compared with the change in the number of G-CSF receptors in bone marrow. The infusion rate-dependent decrease in CLss in control rats confirmed the existence of a saturable elimination mechanism for NTG. The Michaelis-Menten constant (Km) and maximal velocity for this saturable process were estimated to be 107 pM and 15.5 pmol.h-1.kg-1, respectively. The Km for this saturable process was comparable with the dissociation constant (Kd) for the specific binding of NTG to bone marrow cells. After administration of excess NTG, the CLuptake of tracer amounts of 1251-NTG by bone marrow and spleen, which corresponds to the receptor density in the tissues, was reduced at 2 h but gradually recovered. This change in CLuptake corresponds well to the change in the in vitro NTG-binding capacity in each isolated cell. This reduction in CLuptake might be due to the downregulation of G-CSF receptors on the cell surface. On the other hand, the saturable CLss in cyclophosphamide-treated rats was 17% of that in control rats, whereas the saturable CLss in rats given NTG repeatedly was twofold greater than in controls, which is associated with the upregulation of G-CSF receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				Y. Kitamura, M. Hirouchi, H. Kusuhara, J. D. Schuetz, and Y. Sugiyama Increasing Systemic Exposure of Methotrexate by Active Efflux Mediated by Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3) J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 465 - 473. [Abstract] [Full Text] [PDF]

				J. F. Eliason, A. Greway, N. Tare, T. Inoue, S. Bowen, M. Dar, M. Yamasaki, M. Okabe, and I. Horii Extended Activity in Cynomolgus Monkeys of a Granulocyte Colony-Stimulating Factor Mutein Conjugated With High Molecular Weight Polyethylene Glycol Stem Cells, January 1, 2000; 18(1): 40 - 45. [Abstract] [Full Text]

				M. Kato, Y. Kato, and Y. Sugiyama Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen Am J Physiol Endocrinol Metab, May 1, 1999; 276(5): E887 - E895. [Abstract] [Full Text] [PDF]

				K. Suzuki, H. Susaki, S. Okuno, H. Yamada, H. K. Watanabe, and Y. Sugiyama Specific Renal Delivery of Sugar-Modified Low-Molecular-Weight Peptides J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 888 - 897. [Abstract] [Full Text]

				S. Ohdo, N. Arata, T. Furukubo, E. Yukawa, S. Higuchi, S. Nakano, and N. Ogawa Chronopharmacology of Granulocyte Colony-Stimulating Factor in Mice J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 242 - 246. [Abstract] [Full Text]

				M. Kato, H. Kamiyama, A. Okazaki, K. Kumaki, Y. Kato, and Y. Sugiyama Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 520 - 527. [Abstract] [Full Text]

				M. Kato, K. Miura, H. Kamiyama, A. Okazaki, K. Kumaki, Y. Kato, and Y. Sugiyama Immunological Response to Repeated Administration of Recombinant Human Erythropoietin in Rats. Biphasic Effect on Its Pharmacokinetics Drug Metab. Dispos., September 1, 1997; 25(9): 1039 - 1044. [Abstract] [Full Text]